Sign in
SBTX Stock Price, Chart, Stats & News
Silverback Therapeutics, Inc.
Save
550.43M
Market cap
–
Current P/E
–
Forward P/E
SBTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 16.32% |
Operating margin | -212.92% |
Pretax margin | -203.35% |
Net margin | -203.25% |
Effective tax rate | 0.05% |
ROA | -52.28% |
ROE | -100.29% |
D/E | – |
Interest coverage ratio | 69.05x |
SBTX valuation
P/E | – |
P/S | 6.53x |
P/B | 5.06x |
P/CF | -3.39x |
P/FCF | -3.22x |
P/OCF | -3.39x |
PEG | 0.03x |
EV multiple | -3.30x |
About
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Similar securities
Based on sector and market capitalization
Report issue